BRPI0511889A - therapeutic reprogramming, hybrid stem cells and maturation - Google Patents
therapeutic reprogramming, hybrid stem cells and maturationInfo
- Publication number
- BRPI0511889A BRPI0511889A BRPI0511889-1A BRPI0511889A BRPI0511889A BR PI0511889 A BRPI0511889 A BR PI0511889A BR PI0511889 A BRPI0511889 A BR PI0511889A BR PI0511889 A BRPI0511889 A BR PI0511889A
- Authority
- BR
- Brazil
- Prior art keywords
- cells
- stem cells
- maturation
- therapeutic reprogramming
- therapeutically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/061—Sperm cells, spermatogonia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/04—Cells produced using nuclear transfer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer
Abstract
REPROGRAMAçãO TERAPêUTICA, CéLULAS-TRONCO HìBRIDAS E MATURAçãO São providas células programadas terapeuticamente e métodos para fazer tais células. Células programadas terapeuticamente são células-tronco que foram maturadas tal que elas representam um estado mais diferenciado ou um estado menos diferenciado após o contato com fatores estimulatórios. As células reprogramadas terapeuticamente são adequadas para terapia regenerativa celular e têm o potencial de se diferenciar em linhagens celulares mais comprometidas. Adicionalmente, são providas células-tronco híbridas adequadas para reprogramação terapêutica e terapia regenerativa celular.THERAPEUTIC REPROGRAMMING, HYBRID BODY CELLS AND MATURATION Therapeutically programmed cells and methods for making such cells are provided. Therapeutically programmed cells are stem cells that have been matured such that they represent a more differentiated state or a less differentiated state following contact with stimulatory factors. Therapeutically reprogrammed cells are suitable for cell regenerative therapy and have the potential to differentiate into more compromised cell lines. Additionally, hybrid stem cells suitable for therapeutic reprogramming and cell regenerative therapy are provided.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/864,788 US20050090004A1 (en) | 2003-01-16 | 2004-06-08 | Stem cell maturation for all tissue lines |
US58814604P | 2004-07-15 | 2004-07-15 | |
PCT/US2005/005052 WO2005123123A2 (en) | 2004-06-08 | 2005-02-16 | Therapeutic reprogramming, hybrid stem cells and maturation |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0511889A true BRPI0511889A (en) | 2008-01-15 |
Family
ID=35355246
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0511889-1A BRPI0511889A (en) | 2004-06-08 | 2005-02-16 | therapeutic reprogramming, hybrid stem cells and maturation |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1758989A2 (en) |
JP (1) | JP2008501795A (en) |
AU (1) | AU2005253923A1 (en) |
BR (1) | BRPI0511889A (en) |
CA (1) | CA2567692A1 (en) |
RU (1) | RU2006147263A (en) |
WO (1) | WO2005123123A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008104994A2 (en) | 2007-02-28 | 2008-09-04 | Advinus Therapeutics Private Limited | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application |
WO2008149382A1 (en) | 2007-06-08 | 2008-12-11 | Advinus Therapeutics Private Limited | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
EP2090649A1 (en) | 2008-02-13 | 2009-08-19 | Fondazione Telethon | Method for reprogramming differentiated cells |
EP2402327B1 (en) | 2010-06-29 | 2018-03-07 | Impetis Biosciences Ltd. | Acetamide compounds as glucokinase activators, their process and medicinal applications |
EP2796873A1 (en) * | 2013-04-25 | 2014-10-29 | QGel SA | Method for a cell-based drug screening assay and the use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5545499A (en) * | 1998-07-31 | 2000-02-21 | Genzyme Corporation | Improvement of cardiac function by mesenchymal stem cell transplantation |
US20020136709A1 (en) * | 2000-12-12 | 2002-09-26 | Nucleus Remodeling, Inc. | In vitro-derived adult pluripotent stem cells and uses therefor |
JP2004248505A (en) * | 2001-09-21 | 2004-09-09 | Norio Nakatsuji | Undifferentiated fusion cell of somatic cell derived from es cell deficient in part or all of transplantation antigen and method for producing the same |
EP1468088A4 (en) * | 2002-01-16 | 2006-02-15 | Primegen Biotech Llc | Stem cell maturation for all tissue types |
EP1509594A1 (en) * | 2002-05-31 | 2005-03-02 | Apollo Life Sciences Pty Ltd. | Electrofusion of cells and apparatus therefore |
WO2004046312A2 (en) * | 2002-11-15 | 2004-06-03 | The Board Of Trustees Of The University Of Illinois | Methods for in vitro expansion of hematopoietic stem cells |
-
2005
- 2005-02-16 AU AU2005253923A patent/AU2005253923A1/en not_active Abandoned
- 2005-02-16 JP JP2007527196A patent/JP2008501795A/en not_active Withdrawn
- 2005-02-16 RU RU2006147263/14A patent/RU2006147263A/en unknown
- 2005-02-16 BR BRPI0511889-1A patent/BRPI0511889A/en not_active IP Right Cessation
- 2005-02-16 WO PCT/US2005/005052 patent/WO2005123123A2/en active Application Filing
- 2005-02-16 CA CA002567692A patent/CA2567692A1/en not_active Abandoned
- 2005-02-16 EP EP05723204A patent/EP1758989A2/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
RU2006147263A (en) | 2008-07-20 |
WO2005123123A2 (en) | 2005-12-29 |
EP1758989A2 (en) | 2007-03-07 |
CA2567692A1 (en) | 2005-12-29 |
AU2005253923A1 (en) | 2005-12-29 |
WO2005123123A3 (en) | 2006-03-02 |
JP2008501795A (en) | 2008-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ598176A (en) | Disintegrin variants and pharmaceutical uses thereof | |
WO2005005601A8 (en) | Compositions and methods for treating and diagnosing cancer | |
MXPA06001134A (en) | INHIBITORS OF Akt ACTIVITY. | |
MX2009005849A (en) | Compositions and methods to treat cancer with cupredoxins and cpg rich dna. | |
TW200736260A (en) | Inhibitors of Akt activity | |
AU2003285172A8 (en) | Human embryonic stem cell cultures, and compositions and methods for growing same | |
WO2008051568A3 (en) | Methods and compositions for treatment of bone defects with placental cell populations | |
BRPI0507812A (en) | microactivation system, method for epidermal cell microactivation, kit, method for mounting the microactivation device and method for skin microactivation | |
IL179919A0 (en) | Neural stem cells, compositions containing the same and methods for promoting the division thereof | |
NZ603330A (en) | Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies | |
EP1587834A4 (en) | Uses of mammalian cytokine; related reagents | |
MX2007015217A (en) | Automated cell therapy system. | |
WO2006018836A3 (en) | Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues | |
MX2009009225A (en) | Definitive endoderm. | |
WO2001085196A3 (en) | Cxcr4 antagonist treatment of hematopoietic cells | |
MXPA05009694A (en) | Methods of improving skin quality. | |
ATE514772T1 (en) | MULTIPOTENT ADULT STEM CELLS AND METHOD FOR ISOLATION THEREOF | |
MX2018012512A (en) | Placental stem cell populations. | |
WO2011098262A3 (en) | P19arf, hmga2 and mdm2 for use in the diagnosis and treatment of aberrant cell growth | |
SI1941027T1 (en) | Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics. | |
MX2007008980A (en) | Nucleic acids for apoptosis of cancer cells. | |
IL173369A0 (en) | Pharmaceutical combination of g-csf and plgf useful for blood stem cell | |
WO2006113837A3 (en) | Inhibitors of akt activity | |
MX2007000418A (en) | Methods and reagents for treating honeybees for parasitic mites. | |
BRPI0511889A (en) | therapeutic reprogramming, hybrid stem cells and maturation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |